For the First Time Ever, There Will be a Full Week Dedicated to Plasminogen Deficiency (PLGD) !
LAVAL, QC, Nov. 2, 2017 /PRNewswire/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF), ("Prometic") is pleased to invite you to participate in a full week of online activities, dedicated to plasminogen deficiency awareness, from November 6 to 10, 2017.
This initiative, hosted by Prometic, is aimed at raising awareness and improving understanding of the disease and its effects.
Plasminogen Deficiency Awareness Week is a 100% interactive event, freely available at plgdweek.com. For five days, participants will have access to activities including:
- Testimonials from patients and caregivers
- Educational videos and capsules
- Shareable content regarding health and wellness topics
- Supportive ideas and information on how to cope with a rare condition such as Plasminogen Deficiency
To address the needs and interests of a broad stakeholder audience, there will be days dedicated specifically to patients, caregivers and healthcare providers.
Prometic is dedicated to making a difference by developing a plasminogen replacement therapy, for congenital plasminogen deficiency, which is currently under review by the FDA.
"At Prometic, we are passionate about developing solutions for unmet medical needs and rare diseases. We are committed to defining solutions and developing drugs that could address challenging, orphan medical conditions", said Pierre Laurin, President and CEO of Prometic Life Sciences Inc.
Plasminogen Deficiency Awareness Week revolves around sharing knowledge and testimonials. The idea is to build a community of people affected directly or indirectly by the disease – because sharing is a part of healing!
Subscribe at plgdweek.com and share to receive a free lunch box!
About Plasminogen Deficiency
The most common condition associated with plasminogen deficiency is ligneous conjunctivitis, which is characterized by thick, woody (ligneous) growths on the conjunctiva of the eye, and if left untreated, can lead to corneal damage and blindness. Ligneous growths tend to recur after surgical excision, thereby requiring multiple surgeries.
While ligneous conjunctivitis is the best characterized lesion of plasminogen deficiency, hypoplasminogenemia is a multi-systemic disease that can also affect the ears, sinuses, tracheobronchial tree, genitourinary tract, and gingiva. Tracheobronchial lesions including hyper viscous secretions can result in respiratory failure. Hydrocephalus has also been reported in children with severe hypoplasminogenemia, apparently related to the deposition of fibrin in the cerebral ventricular system.
About Prometic Life Sciences Inc.
Prometic Life Sciences Inc. (www.prometic.com) is a long-established biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development. Prometic is active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, cancer and autoimmune diseases/inflammation. A number of plasma-derived and small molecule products are under development for orphan drug indications. Prometic also offers its state-of-the-art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop best-in-class therapeutics and orphan drugs. Headquartered in Laval (Canada), Prometic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and commercial activities in the U.S., Canada, Europe and Asia.
Forward Looking Statements
This press release contains forward-looking statements about Prometic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Prometic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Prometic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Prometic's Annual Information Form for the year ended December 31, 2016, under the heading "Risk and Uncertainties related to Prometic's business". As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.
SOURCE ProMetic Life Sciences Inc.
Share this article